Soligenix Gross Margin 2010-2022 | SNGX

Current and historical gross margin for Soligenix (SNGX) over the last 10 years. The current gross profit margin for Soligenix as of March 31, 2022 is %.
Soligenix Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2022-03-31 $0.00B 0 nan%
2021-12-31 $0.00B 0 nan%
2021-09-30 $0.00B 0 nan%
2021-06-30 $0.00B 0 0.00%
2021-03-31 $0.00B 0 0.00%
2020-12-31 $0.00B 0 0.00%
2020-09-30 $0.00B 0 0.00%
2020-06-30 $0.00B 0 0.00%
2020-03-31 $0.01B 0 0.00%
2019-12-31 $0.01B 0 0.00%
2019-09-30 $0.01B 0 0.00%
2019-06-30 $0.01B 0 0.00%
2019-03-31 $0.01B 0 0.00%
2018-12-31 $0.01B 0 0.00%
2018-09-30 $0.01B 0 0.00%
2018-06-30 $0.01B 0 0.00%
2018-03-31 $0.01B 0 0.00%
2017-12-31 $0.01B 0 0.00%
2017-09-30 $0.01B 0 0.00%
2017-06-30 $0.01B 0 0.00%
2017-03-31 $0.01B $0.00B 11.11%
2016-12-31 $0.01B $0.00B 9.09%
2016-09-30 $0.01B $0.00B 8.33%
2016-06-30 $0.01B $0.00B 15.38%
2016-03-31 $0.01B $0.00B 9.09%
2015-12-31 $0.01B $0.00B 11.11%
2015-09-30 $0.01B $0.00B 12.50%
2015-06-30 $0.01B $0.00B 14.29%
2015-03-31 $0.01B $0.00B 14.29%
2014-12-31 $0.01B $0.00B 14.29%
2014-09-30 $0.01B $0.00B 16.67%
2014-06-30 $0.00B 0 0.00%
2014-03-31 $0.00B 0 0.00%
2013-12-31 $0.00B 0 0.00%
2013-09-30 $0.00B 0 0.00%
2013-06-30 $0.00B 0 0.00%
2013-03-31 $0.00B 0 0.00%
2012-12-31 $0.00B 0 0.00%
2012-09-30 $0.00B 0 0.00%
2012-06-30 $0.01B $0.01B 55.56%
2012-03-31 $0.01B $0.01B 62.50%
2011-12-31 $0.01B $0.01B 62.50%
2011-09-30 $0.01B $0.01B 71.43%
2011-06-30 $0.00B 0 0.00%
2011-03-31 $0.00B 0 0.00%
2010-12-31 $0.00B 0 0.00%
2010-09-30 $0.00B $0.00B 50.00%
2010-06-30 $0.00B $0.00B 50.00%
2010-03-31 $0.00B $0.00B 50.00%
2009-12-31 $0.00B $0.00B 33.33%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.026B $0.001B
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00